Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. (Q46844231)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

author name string

Shaul Atar

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

Yumei Ye

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

Yu Lin

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

Sheldon Y Freeberg

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

Shawn P Nishi

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

Salvatore Rosanio

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

Ming-He Huang

7

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

Barry F Uretsky

8

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

Jose R Perez-Polo

9

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

Yochai Birnbaum

10

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

publication date

9 December 2005

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

American Journal of Physiology Heart and Circulatory Physiology

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

290

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

H1960-8

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Nitric oxide as a mediator of delayed pharmacological (A(1) receptor triggered) preconditioning; is eNOS masquerading as iNOS?

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Reduction of infarct size by short-term pretreatment with atorvastatin

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Cerivastatin inhibits proliferation of interleukin-1 beta-induced rat mesangial cells by enhanced formation of nitric oxide

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

The nitric oxide hypothesis of late preconditioning

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Late preconditioning induced by NO donors, adenosine A1 receptor agonists, and delta1-opioid receptor agonists is mediated by iNOS

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Protein S-nitrosylation: purview and parameters

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Protein S-nitrosylation: a physiological signal for neuronal nitric oxide

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Inducible nitric oxide synthase mediates delayed cardioprotection induced by morphine in vivo: evidence from pharmacologic inhibition and gene-knockout mice

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Statin blocks Rho/Rho-kinase signalling and disrupts the actin cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Neuroprotection mediated by changes in the endothelial actin cytoskeleton.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

COX-2 and iNOS in opioid-induced delayed cardioprotection in the intact rat.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Signal transduction of ischemic preconditioning

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

(S)NO signals: translocation, regulation, and a consensus motif

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Selective activation of E-type prostanoid(3)-receptors reduces myocardial infarct size. A novel insight into the cardioprotective effects of prostaglandins

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Mechanism of cyclooxygenase-2 upregulation in late preconditioning

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Inducible nitric oxide synthase mediates delayed myocardial protection induced by activation of adenosine A(1) receptors: evidence from gene-knockout mice

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01137.2005

21 January 2018

Identifiers

10.1152/AJPHEART.01137.2005

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16339820

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46844231&oldid=909566575"